Inhibition of HIV-1 in CEM cells by a potent TAR decoy

S. W. Lee, H. F. Gallardo, O. Gaspar, C. Smith, Eli Gilboa

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

TAR decoys are short RNA oligonucleotides, corresponding to the HIV TAR sequence, which inhibit HIV expression and replication by blocking the binding of the HIV regulatory protein Tat to the authentic TAR region. In previous studies, TAR decoys expressed from a tRNA polIII promoter were moderately effective at inhibiting HIV in isolated human T cell lines and less effective at inhibiting HIV in peripheral blood CD4+ T cells. In this study, a series of modifications was introduced into the tRNA expression cassette in order to improve their effectiveness. These modifications included the addition of sequences which are predicted to have stem-loop secondary structures and addition of a wild-type tRNA processing site. TAR decoy RNA expressed in CEM cells from modified tRNA-based expression cassettes yielded five- to 20-fold more TAR transcripts than unmodified tRNA-based expression cassettes. HIV replication, as measured by a flow cytometric method to quantify intracellular viral p24 expression, was significantly reduced in polyclonal populations of CEM cells expressing a modified tRNA-TAR transcript that contains a wild-type tRNA processing site and stem-loops 5' and 3' to the TAR sequence. Similar modifications to the tRNA expression cassette also increased the intracellular concentration of a random test oligonucleotide, indicating that this improved expression system may also be useful for antisense and ribozyme based gene inhibition strategies.

Original languageEnglish
Pages (from-to)377-384
Number of pages8
JournalGene Therapy
Volume2
Issue number6
StatePublished - Jan 1 1995
Externally publishedYes

Fingerprint

Transfer RNA
HIV-1
HIV
Oligonucleotides
Human Immunodeficiency Virus tat Gene Products
RNA
T-Lymphocytes
Catalytic RNA
Cell Line
Population
Genes

Keywords

  • gene therapy
  • HIV
  • TAR decoy
  • tRNA polIII promoter

ASJC Scopus subject areas

  • Genetics

Cite this

Lee, S. W., Gallardo, H. F., Gaspar, O., Smith, C., & Gilboa, E. (1995). Inhibition of HIV-1 in CEM cells by a potent TAR decoy. Gene Therapy, 2(6), 377-384.

Inhibition of HIV-1 in CEM cells by a potent TAR decoy. / Lee, S. W.; Gallardo, H. F.; Gaspar, O.; Smith, C.; Gilboa, Eli.

In: Gene Therapy, Vol. 2, No. 6, 01.01.1995, p. 377-384.

Research output: Contribution to journalArticle

Lee, SW, Gallardo, HF, Gaspar, O, Smith, C & Gilboa, E 1995, 'Inhibition of HIV-1 in CEM cells by a potent TAR decoy', Gene Therapy, vol. 2, no. 6, pp. 377-384.
Lee SW, Gallardo HF, Gaspar O, Smith C, Gilboa E. Inhibition of HIV-1 in CEM cells by a potent TAR decoy. Gene Therapy. 1995 Jan 1;2(6):377-384.
Lee, S. W. ; Gallardo, H. F. ; Gaspar, O. ; Smith, C. ; Gilboa, Eli. / Inhibition of HIV-1 in CEM cells by a potent TAR decoy. In: Gene Therapy. 1995 ; Vol. 2, No. 6. pp. 377-384.
@article{c5e09ef532164a2693130ca69ca76461,
title = "Inhibition of HIV-1 in CEM cells by a potent TAR decoy",
abstract = "TAR decoys are short RNA oligonucleotides, corresponding to the HIV TAR sequence, which inhibit HIV expression and replication by blocking the binding of the HIV regulatory protein Tat to the authentic TAR region. In previous studies, TAR decoys expressed from a tRNA polIII promoter were moderately effective at inhibiting HIV in isolated human T cell lines and less effective at inhibiting HIV in peripheral blood CD4+ T cells. In this study, a series of modifications was introduced into the tRNA expression cassette in order to improve their effectiveness. These modifications included the addition of sequences which are predicted to have stem-loop secondary structures and addition of a wild-type tRNA processing site. TAR decoy RNA expressed in CEM cells from modified tRNA-based expression cassettes yielded five- to 20-fold more TAR transcripts than unmodified tRNA-based expression cassettes. HIV replication, as measured by a flow cytometric method to quantify intracellular viral p24 expression, was significantly reduced in polyclonal populations of CEM cells expressing a modified tRNA-TAR transcript that contains a wild-type tRNA processing site and stem-loops 5' and 3' to the TAR sequence. Similar modifications to the tRNA expression cassette also increased the intracellular concentration of a random test oligonucleotide, indicating that this improved expression system may also be useful for antisense and ribozyme based gene inhibition strategies.",
keywords = "gene therapy, HIV, TAR decoy, tRNA polIII promoter",
author = "Lee, {S. W.} and Gallardo, {H. F.} and O. Gaspar and C. Smith and Eli Gilboa",
year = "1995",
month = "1",
day = "1",
language = "English",
volume = "2",
pages = "377--384",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Inhibition of HIV-1 in CEM cells by a potent TAR decoy

AU - Lee, S. W.

AU - Gallardo, H. F.

AU - Gaspar, O.

AU - Smith, C.

AU - Gilboa, Eli

PY - 1995/1/1

Y1 - 1995/1/1

N2 - TAR decoys are short RNA oligonucleotides, corresponding to the HIV TAR sequence, which inhibit HIV expression and replication by blocking the binding of the HIV regulatory protein Tat to the authentic TAR region. In previous studies, TAR decoys expressed from a tRNA polIII promoter were moderately effective at inhibiting HIV in isolated human T cell lines and less effective at inhibiting HIV in peripheral blood CD4+ T cells. In this study, a series of modifications was introduced into the tRNA expression cassette in order to improve their effectiveness. These modifications included the addition of sequences which are predicted to have stem-loop secondary structures and addition of a wild-type tRNA processing site. TAR decoy RNA expressed in CEM cells from modified tRNA-based expression cassettes yielded five- to 20-fold more TAR transcripts than unmodified tRNA-based expression cassettes. HIV replication, as measured by a flow cytometric method to quantify intracellular viral p24 expression, was significantly reduced in polyclonal populations of CEM cells expressing a modified tRNA-TAR transcript that contains a wild-type tRNA processing site and stem-loops 5' and 3' to the TAR sequence. Similar modifications to the tRNA expression cassette also increased the intracellular concentration of a random test oligonucleotide, indicating that this improved expression system may also be useful for antisense and ribozyme based gene inhibition strategies.

AB - TAR decoys are short RNA oligonucleotides, corresponding to the HIV TAR sequence, which inhibit HIV expression and replication by blocking the binding of the HIV regulatory protein Tat to the authentic TAR region. In previous studies, TAR decoys expressed from a tRNA polIII promoter were moderately effective at inhibiting HIV in isolated human T cell lines and less effective at inhibiting HIV in peripheral blood CD4+ T cells. In this study, a series of modifications was introduced into the tRNA expression cassette in order to improve their effectiveness. These modifications included the addition of sequences which are predicted to have stem-loop secondary structures and addition of a wild-type tRNA processing site. TAR decoy RNA expressed in CEM cells from modified tRNA-based expression cassettes yielded five- to 20-fold more TAR transcripts than unmodified tRNA-based expression cassettes. HIV replication, as measured by a flow cytometric method to quantify intracellular viral p24 expression, was significantly reduced in polyclonal populations of CEM cells expressing a modified tRNA-TAR transcript that contains a wild-type tRNA processing site and stem-loops 5' and 3' to the TAR sequence. Similar modifications to the tRNA expression cassette also increased the intracellular concentration of a random test oligonucleotide, indicating that this improved expression system may also be useful for antisense and ribozyme based gene inhibition strategies.

KW - gene therapy

KW - HIV

KW - TAR decoy

KW - tRNA polIII promoter

UR - http://www.scopus.com/inward/record.url?scp=0029156928&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029156928&partnerID=8YFLogxK

M3 - Article

C2 - 7584112

AN - SCOPUS:0029156928

VL - 2

SP - 377

EP - 384

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 6

ER -